What is Puma Biotechnology, Inc. (PBYI)?

Puma Biotechnology, Inc. (PBYI) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of PBYI?

The current price of PBYI is $10.54. Prices are updated in real time on Stocks360.

What is PBYI's price-to-earnings (PE) ratio?

PBYI's trailing twelve-month PE ratio is 19.66, based on current price and earnings per share data available on Stocks360.

What is PBYI's market capitalization?

PBYI's market capitalization is $544,075,496.00, placing it in the small-cap tier.

Puma Biotechnology, Inc. (PBYI)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$10.54

Market Cap

$544.08M

PE (TTM)

19.66

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.21

Day Range

$10.51 – $10.81

52-wk Range

$4.58 – $11.50

Avg Volume

N/A

Volume

224.28K

Puma Biotechnology, Inc. (PBYI) is a publicly traded company in the Healthcare sector. Latest price: $10.54. Market cap $544.08M. Trailing PE 19.66. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 6 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $5.46 2026-10-29 · $10.54 (+93.04%)

Earnings

Most Recent

Aug 6, 2026

EPS $0.19 vs est. $0.04

Beat by $0.15

Next Earnings

Nov 5, 2026

EPS estimate $0.09

Proprietary Signals

Signal snapshot temporarily unavailable.

About Puma Biotechnology, Inc.

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	19.66×
P/S (TTM)	2.35×
P/B	3.88×
P/FCF (TTM)	13.22×
EV / EBITDA	11.34×
EV / Sales	2.22×
Earnings Yield	4.98%
Free Cash Flow Yield	7.56%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$512.36M
Revenue (TTM)	$231.24M
Net Income (TTM)	$27.07M
Free Cash Flow (TTM)	$44.17M
Net Debt	-$31.72M
Working Capital	$95.25M
Gross Margin	74.83%
Operating Margin	13.16%
Net Margin	11.55%
Return on Equity	20.85%
Return on Invested Capital	18.20%